Jenny Rooke, founder and managing partner of Genoa Ventures (Genoa Ventures)
Q&A: How to attract the eye of an early investor in biotech R&D tools
SAN FRANCISCO — As early-stage biotechs grapple with the funding and IPO challenges associated with a down economy, some adjacent and more recession-proof areas are still seeing robust investments.
Jenny Rooke, founder and managing partner of Genoa Ventures, sat down with Endpoints News yesterday to talk about her investments in early-stage companies that blend biology and technology, but aren’t working on a therapeutic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
